Pharma Company Expands Presence In Government & Institutional Healthcare; Stock Hits Upper Circuit

Shukra Pharmaceuticals Ltd. has announced that it has been granted permission by Wockhardt Limited, a prominent international pharmaceutical company, to market, distribute, and supervise its products throughout all ESIC/ESIS Hospitals, Defence Hospitals, AFMSD, and DGAFMS facilities in India on a PAN India basis.

This non-exclusive permission, which was obtained on September 9, 2025, and remains valid until March 2026, allows the company the right to quote, receive orders, generate invoices, and accept payments directly on behalf of Wockhardt Limited.

The medicinal products contain premium, cutting-edge anti-infective formulations, including MIQNAF® (Nafithromycin) and EMROK® (Levonadifloxacin), which are groundbreaking antibiotics created to treat serious illnesses.

The Board and Management of Shukra Pharmaceuticals Limited are confident that this strategic distributorship from Wockhardt Limited, a reputable name in the global healthcare industry, is going to have a beneficial and lasting effect on the company's financial and operational performance, making it an essential turning point in its expansion trajectory.

"The arrangement will strengthen the Company's presence in institutional and government healthcare networks across India, enhance revenue visibility and operational footprint, create long-term value for shareholders by aligning with India's expanding healthcare and hospital infrastructure," said Shukra Pharmaceuticals in a stock exchange filing.

Additionally, Shukra Pharmaceuticals has declared that Tuesday, September 30, 2025, will be the date of the 32nd Annual General Meeting (AGM) of the company's members.

"The remote e-voting period begins on Saturday, September 27, 2025 at 09:00 A.M. and ends on Monday, September 29, 2025 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. Tuesday, September 23, 2025, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Tuesday, September 23, 2025," Shukra Pharmaceuticals said in its FY25 annual report.

At its board meeting on 04/06/2025, the company's board of directors recommended a final dividend of Rs 0.01/-per equity share of Rs. 10/-, subject to the approval of the company's shareholders at the subsequent Annual General Meeting. This recommendation was made in light of the company's amazing performance in the fiscal year 2024-2025.

"The board has fixed Saturday, September 13, 2025 as the "Record Date" for determining entitlement of members to dividend for the financial year ended March 31, 2025," said Shukra Pharmaceuticals in its annual report.

"The dividend on equity shares, if declared at the Meeting as recommended by the Board of Directors, will be credited / dispatched to those members whose names appear on the Company's Register of Members on the Record Date, in respect of the shares held in dematerialized mode and physical mode, the dividend will be paid to members whose names are furnished by National Securities Depository Limited [NSDL] and Central Depository Services (India) Limited [CDSL] as beneficial owners as on that date," Shukra Pharmaceuticals further informed stock exchanges.

With a 2 percent rise over the previous close, Shukra Pharmaceuticals Ltd.'s shares landed in an upper circuit limit at Rs 27.78 per share on Thursday, September 11. The stock is presently trading at Rs 27.78, very near to its 52-week high of Rs 28.92, which was reached on September 5, 2025, and has demonstrated impressive performance over the 1 year. This indicates that the stock has shown remarkable gains from its 52-week low of Rs 5.75 on November 21, 2024, signaling a dramatic multi-fold rebound.